sur VALBIOTIS (EPA:ALVAL)
Valbiotis Reports 2025 Financial Results and Strategic Advancements
Valbiotis SA has released its 2025 financial results, showcasing significant progress in commercial expansion and operational foundations. The company's revenue increased to €905,000, a noteworthy growth compared to €175,000 in 2024, attributed to enhanced product offerings and a strengthened presence in pharmacies.
The year saw a strategic focus on commercialization, with operating expenses reduced by 30% amid increased investments in sales and marketing. Valbiotis also expanded its international footprint with partnerships in Asia and the Middle East, positioning itself for further growth. Despite a net loss of €9.4 million, the cash position remains robust at €8.7 million, supporting upcoming initiatives in 2026.
The company's commitment to its roadmap, including new product launches and strategic alliances, emphasizes its long-term goals. CEO Sébastien Peltier affirmed confidence in Valbiotis' future, buoyed by recent milestones and a focused strategy on commercialization and international partnerships.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de VALBIOTIS